So-called undruggable proteins — those that supposedly can’t be targeted by pharmaceuticals — represent a big barrier in discovering new drugs for complex diseases like cancer, autoimmune disorders, and others that continue to be major causes of disability and death. As someone who has spent decades in academic research and more recently in the biotech industry, I’m betting that the biopharmaceutical research community will overcome this problem to treat, and potentially cure, these and other diseases.
Why? In part because the dominant model that has ruled drug discovery for decades is starting to give way to a new approach that harnesses the power of biology to tackle previously undruggable disease targets. This shift represents a staggering potential for advancement.